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USA; 12OptumLabs, Cambridge, MA, USAA B S T R A C TEvidence-based health care decisions are best informed by comparisons
of all relevant interventions used to treat conditions in speciﬁc patient
populations. Observational studies are being performed to help ﬁll
evidence gaps. Widespread adoption of evidence from observational
studies, however, has been limited because of various factors, including
the lack of consensus regarding accepted principles for their evaluation
and interpretation. Two task forces were formed to develop question-
naires to assist decision makers in evaluating observational studies, with
one Task Force addressing retrospective research and the other Task
Force addressing prospective research. The intent was to promote a
structured approach to reduce the potential for subjective interpretation
of evidence and drive consistency in decision making. Separately
developed questionnaires were combined into a single questionnaire
consisting of 33 items. These were divided into two domains: relevancesee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2013.12.011
uams.edu.
ndence to: Bradley C. Martin, Division of Pharmace
5.and credibility. Relevance addresses the extent to which ﬁndings, if
accurate, apply to the setting of interest to the decision maker.
Credibility addresses the extent to which the study ﬁndings accurately
answer the study question. The questionnaire provides a guide for
assessing the degree of conﬁdence that should be placed from observa-
tional studies and promotes awareness of the subtleties involved in
evaluating those.
Keywords: bias, checklist, comparative effectiveness research, con-
founding, consensus, credibility, decision making, prospective obser-
vational study, quality, questionnaire, relevance, retrospective
observational study, validity.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Four Good Practices task forces developed consensus-based
questionnaires to help decision makers evaluate: 1) prospective
and 2) retrospective observational studies, 3) network meta-
analysis (indirect treatment comparison), and 4) decision analytic
modeling studies with greater uniformity and transparency [1,2].
The primary audiences of these questionnaires are assessors and
reviewers of health care research studies for health technology
assessment, drug formulary, and health care services decisions
who have varying levels of knowledge and expertise. As dis-
cussed above, the prospective and retrospective observational
task forces, while ultimately coordinating their efforts, workedindependently. The work products of these two task forces were
quite similar, and based on feedback from reviewers a single
questionnaire for observational studies was developed.
Although randomized controlled trials (RCTs) are often sought
to inform health system decisions, there is increasing recognition
of the limitations of relying on RCTs alone. These studies may not
exist because of ﬁnancial, ethical, or time limitations or if available
they may lack sufﬁcient information to guide decision making,
which needs input from real-world conditions, diverse populations,
or practice settings. Other types of studies, such as observational,
modeling, and network meta-analysis, are increasingly sought to
ﬁll this gap [3]. There may be barriers, however, to the use of these
studies due to the limited number of accepted principles for theirociety for Pharmacoeconomics and Outcomes Research (ISPOR).
utical Evaluation and Policy, 4301 West Markham Street, Slot 522,
Background to the Task Force
On May 21, 2011, the Board of Directors approved, in principle,
ISPOR’s participation with the Academy of Managed Care
Pharmacy (AMCP) and the National Pharmaceutical Council
(NPC) in the Comparative Effectiveness Research Collaborative
Initiative (CER-CI) for advancing appropriate use of outcomes
research evidence to improve patient health outcomes. ISPOR’s
contribution to the CER-CI was to develop articles on how to
assess prospective and retrospective observational studies,
indirect treatment comparison (network meta-analysis), and
decision analytic modeling studies to inform health care
decision making. Four Good Practice task forces were created
to develop these articles. Task Force Chairs were identified from
leaders of ISPOR Good Research Practices task forces. Each Task
Force consisted of two members from the AMCP, the NPC, and
the ISPOR.Each Task Force met independently via teleconfer-
ence. In addition, the Task Force Chairs met via teleconferences
and face-to-face meetings held on April 20, 2012 (San Francisco,
CA, USA), June 3, 2012 (Washington, DC, USA), June 28-29, 2012
(Boston, MA, USA), November 4, 2012 (Berlin, Germany), and
May 21, 2013 (New Orleans, LA, USA), to coordinate a common
outline and format for these articles. A focus group representing
the US formulary decision-making community (22 participants)
was convened April 20, 2012, at the AMCP Meeting, San
Francisco, CA, USA, for feedback on the draft outline, format,
and content of the assessment articles. The content of these
reports was presented for comment at the ISPOR Annual
International Meetings held June 4, 2012, and May 22, 2013,
and the European Congress held November 5 and 6, 2012. Draft
prospective observational studies and retrospective observa-
tional studies Task Force reports were sent for comment to their
respective review group. Comments for each group were
considered, and final draft reports were sent to the ISPOR
membership for comment on September 5, 2013. Overall, there
were 82 written comments for the retrospective Task Force
report and 57 written comments for the prospective Task Force
report. A number of reviewers commented on the overlap
between the two reports. Based on these comments, the
prospective and retrospective Task Force reports were com-
bined. All written comments are published on the ISPOR Web
site, which can be accessed via the Research menu on ISPOR’s
home page: http://www.ispor.org. The final report was sub-
mitted to Value in Health.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 4 3 – 1 5 6144evaluation and interpretation. There is a need for transparent and
uniform ways to assess their quality [4]. A structured approach
reduces the potential for subjectivity to affect the interpretation of
evidence and can promote consistency in decision making [5].
Previous tools, including grading systems, scorecards, and
checklists, have been developed to facilitate structured
approaches to critically appraising clinical research [6,7]. Some
are elaborate, requiring software and deliberation among a broad
range of experts [8], whereas others are very simple, using
scoring systems best suited for randomized clinical trials [9].
With the goal of creating a questionnaire that would promote
awareness of the issues related to alternative study designs to a
wide audience of users, it was believed that a simple, time-
efﬁcient, user-friendly questionnaire incorporating epidemiolog-
ical principles is needed to give decision makers the means to
more appropriately consider results from alternative research
designs.
Development of this questionnaire was informed by previous
efforts and with several guiding principles derived from a focus
group of payers. First, questionnaires would be used by individ-
uals with a broad range of expertise including many without in-
depth training in study design and statistics. Second, question-
naires had to be sufﬁciently comprehensive to promote aware-
ness of the appropriate application of different study designs to
decision making; we also sought to produce a questionnaire that
would include explanations of core concepts and prompt users to
obtain additional education on the underlying methodologies.
Last, the use of questionnaires would need to be facilitated by
comprehensive educational programs.
Although some might argue that there is no clear distinction
between retrospective and prospective observational studies,
these were separately considered by two previous ISPOR Good
Research Practices task forces [10–13]. The working deﬁnitions of
these task forces were used in guiding the work in this new
initiative. Prospective observational studies were deﬁned as those in which
participants are not randomized or otherwise assigned to an
exposure and for which the consequential outcomes of
interest occur after study commencement (including creation
of a study protocol and analysis plan, and study initiation).
They are often longitudinal in nature. Exposure to any of theinterventions being studied may or may not have been
recorded before the study initiation such as when a prospec-
tive observational study uses an existing registry cohort.
Exposure may include a pharmaceutical intervention, surgery,
medical device, prescription, or decision to treat. Retrospective observational studies were deﬁned as those that
use existing data sources in which both exposure and out-
comes have already occurred.
Prospective observational studies have the potential advant-
age of collecting the speciﬁc study measures desired; retrospec-
tive studies use existing data sets but have the advantage of
generally being less costly and require less time to conduct.
Ultimately the principles identiﬁed by the two task forces for
evaluating prospective and retrospective observational studies
were sufﬁciently similar that a common questionnaire was
adopted; however, the distinction between prospective and
retrospective perspectives can be important in using this ques-
tionnaire and explanations provided with the questionnaire draw
on both perspectives. Because the focus of these efforts was
speciﬁcally on comparative effectiveness research, considera-
tions applying to pharmacovigilance, safety surveillance, and
economic analyses were not addressed.Questionnaire Development
The ﬁrst issue addressed was whether the questionnaires devel-
oped for this joint initiative should be linked to checklists,
scorecards, or annotated scorecards. Concerns were raised that
a scoring system may be misleading if it did not have adequate
measurement properties. Scoring systems have been shown to be
problematic in the interpretation of randomized trials [14].
An alternative to a scorecard is a checklist. The Task Force
members, however, believed that checklists might also mislead
users because a study may satisfy nearly all the elements of a
checklist and still harbor “fatal ﬂaws” (deﬁned as design, execution,
or analysis elements of the study that by themselves may signiﬁ-
cantly undermine the validity of the results). Moreover, users might
tend to add the number of positive or negative elements and
convert it to a score, and then apply the score to their overall
assessment of the evidence implicitly (and incorrectly) giving equal
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may depend on other evidence that addresses the speciﬁc issue or
the decision being made. A questionnaire without an accompany-
ing score or checklist was felt to be the best way to allow analysts to
be aware of the strengths and weaknesses of each piece of evidence
and apply their own reasoning.
Questions were developed on the basis of a review of items in
previous questionnaires and guidance documents, previous
ISPOR Task Force recommendations [10–13], and methods and
reporting guidances (including Grading of Recommendations,
Assessment, Development and Evaluation, STrengthening the
Reporting of OBservational studies in Epidemiology, and the
European Network of Centres for Pharmacoepidemiology and
Pharmacovigilance) [3,15–35]. The retrospective committee iden-
tiﬁed all items and themes in these guidance documents and
created a list of 174 items. Themes assessing observational study
quality not originally in question format were reworded in yes/no
question format. Items from previous guidance were categorized
and redundant themes were removed. The 174 items were rated
by the committee members across ﬁve domains: credibility,
relevance, feasibility, clarity, and uniqueness. Items that were
rated low on these ﬁve domains were considered for removal by
the committee by consensus of the committee members, result-
ing in 99 items. The prospective committee followed the same
process and created a similar list. After preliminary user testing,
items were further reduced and grouped into common concep-
tual domains for each of the prospective and retrospective
questionnaires. At a meeting of the chairs of the four task forces,
the domains across all four questionnaires were harmonized as
much as possible, and then grouped into two common sections
—“Relevance” and “Credibility”—on the basis of key elements
essential to evaluating comparative effectiveness evidence.
Four identical questions were developed for the relevance
section for this and the other questionnaires developed in this
joint initiative. Credibility was further divided into several key
domains. For this questionnaire to obtain broad acceptance, and
based on early feedback, it was decided to limit the questionnaire
length to about 30 items. Whenever possible, efforts were madeFig. 1 – Summary ﬂowchart for observational study assessment
“weakness” had been detected in one of the elements that suppo
potential “fatal ﬂaw” had been detected.to avoid the use of jargon and to use similar wording, where
appropriate, across all the questionnaires. There was substantial
overlap in the design and ﬂow of the questionnaires for prospec-
tive and retrospective studies. Following the suggestion by a
number of reviewers to combine the two observational study
questionnaires, collaboration between the two observational
study task forces led to an agreement on a single set of questions
and their wording. The logic ﬂow to assess credibility is shown in
Figure 1.How to Use the Questionnaire
Questions that fall under the main categories of relevance and
credibility appear in Table 1. Explanations of each question along
with speciﬁc deﬁnitions and issues to consider (formulated as
subquestions) are provided in the following section, to facilitate
understanding of the appropriate use of the questionnaire.
The questionnaire is an organized series of items with “yes”
“no” binary response choices with strengths and weaknesses
coded depending on the wording of the item. Users are encour-
aged to evaluate each item and determine if the study met or did
not meet the criteria captured in each item, however, a series of
“can't answer” response choices are available to capture instan-
ces when the reporting is inadequate or when the user does not
have sufﬁcient training to evaluate the item. Upon completion of
questions in the relevance section, users are asked to rate
whether the study is sufﬁcient or insufﬁcient to inform their
decision making. If a study is not considered sufﬁciently relevant,
a user can then opt to truncate the review of its credibility. In the
credibility category, the user answers a series of individual yes/no
items and then rates each domain as a “strength,” a “weakness,”
or “neutral.” On the basis of these evaluations, the user then
similarly rates the credibility of the research study as either
“sufﬁcient” or “insufﬁcient” to inform decision making. For some
questions in the credibility section, a user will be notiﬁed that he
or she had detected a “fatal ﬂaw.” The presence of a fatal ﬂaw
suggests a signiﬁcant opportunity for the ﬁndings to bequestionnaire. Red thumbs down icons indicate that a
rt credibility. Red skull and cross-bones icons indicate that a
Table 1 – Questionnaire* to assess the relevance and credibility of a prospective observational study.
S. no. Question Strength Weakness Can’t answer
Not
applicable
Not
reported
Not enough
information
Not
enough
training
Relevance questions
1 Is the population relevant? Yes No
2 Are any relevant
interventions missing?
No Yes
3 Are the outcomes relevant? No Yes
4 Is the context (settings and
practice patterns)
applicable?
Yes No
Comments
Credibility questions
Design
1 Were the study hypotheses
or goals prespeciﬁed a
priori?
Yes No
2 If one or more comparison
groups were used, were
they concurrent
comparators or did they
justify the use of historical
comparison group(s)?
Yes No
3 Was there evidence that a
formal study protocol
including an analysis plan
was speciﬁed before
executing the study?
Yes No
4 Were sample size and
statistical power to detect
differences addressed?
Yes No
5 Was a study design used to
minimize or account for
confounding?
Yes No
6 Was the follow-up period of
sufﬁcient duration to
detect differences
addressed?
Yes No
7 Were the sources, criteria,
and methods for selecting
participants appropriate to
address the study
questions/hypotheses?
Yes No
8 Were the study groups
selected so that
comparison groups would
be sufﬁciently similar to
each other (e.g., either by
restriction or recruitment
based on the same
indications for treatment)?
Yes No
Comments
Data
1 Were the data sources
sufﬁcient to support the
study?
Yes No
2 Was exposure deﬁned and
measured in a valid way?
Yes No
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Table 1 – continued
S. no. Question Strength Weakness Can’t answer
Not
applicable
Not
reported
Not enough
information
Not
enough
training
3 Were the primary outcomes
deﬁned and measured in a
valid way?
Yes No
4 Was the follow-up time
similar among comparison
groups or were the
differences in follow-up
accounted for in the
analyses?
Yes No
Comments
Analyses
1 Was there a thorough
assessment of potential
measured and
unmeasured confounders?
Yes No
2 Were analyses of subgroups
or interaction effects
reported for comparison
groups?
Yes No
3 Were sensitivity analyses
performed to assess the
effect of key assumptions
or deﬁnitions on
outcomes?
Yes No
Comments
Reporting
1 Was the number of
individuals screened or
selected at each stage of
deﬁning the ﬁnal sample
reported?
Yes No
2 Were the descriptive
statistics of the study
participants adequately
reported?
Yes No
3 Did the authors describe the
key components of their
statistical approaches?
Yes No
4 Were confounder-adjusted
estimates of treatment
effects reported?
Yes No
5 Did the authors describe the
statistical uncertainty of
their ﬁndings?
Yes No
6 Was the extent of missing
data reported?
7 Were absolute and relative
measures of treatment
effect reported?
Yes No
Comments
Interpretation
1 Were the results consistent
with prior known
information or if not was
Yes No
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Table 1 – continued
S. no. Question Strength Weakness Can’t answer
Not
applicable
Not
reported
Not enough
information
Not
enough
training
an adequate explanation
provided?
2 Are the observed treatment
effects considered
clinically meaningful?
Yes No
3 Are the conclusions
supported by the data and
analysis presented?
Yes No
4 Was the effect of
unmeasured confounding
discussed?
Yes No
Comments
Conﬂicts of
interest
1 Were there any potential
conﬂicts of interest?
Yes No
2 If there were potential
conﬂicts of interest, were
steps taken to address
these?
Yes No
Comments
Relevance questions relate to the usefulness of the observational study to inform health care decision making. Each question will be scored
with Yes/No/Can’t Answer. Based on the scoring of the individual questions, the overall relevance of the observational study needs to be judged
as Sufﬁcient or Insufﬁcient.
If the observational study is considered sufﬁciently relevant, the credibility is going to be assessed. The credibility is captured with questions
in the following six domains: Design, Data, Analysis, Reporting, Interpretation, and Conﬂict of interest. Each question will be scored with Yes/No/
Can’t Answer. Based on the number of questions scored satisfactory in each domain, an overall judgment of the strength of each domain needs
to be provided: Strength/Neutral/Weakness/Fatal ﬂaw. If any one of the items is scored as a no resulting in a fatal ﬂaw, the overall domain will be
scored as a fatal ﬂaw and the study may have serious validity issues. Based on the domain judgments, the overall credibility of the study will
be judged as Sufﬁcient or Insufﬁcient.
* The questionnaire consists of 33 questions related to the relevance and credibility of a prospective observational study.
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caution in applying the ﬁndings to inform decisions. The occur-
rence of a fatal ﬂaw, however, does not prevent a user from
completing the questionnaire nor does it require the user to judge
the evidence as insufﬁcient for use in decision making. The
presence of a fatal ﬂaw is intended to raise a strong caution
and should be carefully considered when the overall body of
evidence is reviewed.Questionnaire Items
Relevance
Relevance addresses whether the results of the study/apply to
the setting of interest to the decision maker. It addresses issues
of external validity similar to the population, interventions,
comparators, outcomes, and setting framework from evidence-
based medicine [36]. There is no correct answer for relevance.
Relevance is determined by each decision maker, and the
relevance assessment determined by one decision maker will
not necessarily apply to other decision makers. Individual studies
may be designed with the perspective of particular decision
makers in mind (e.g., payer or provider).Is the population relevant?
This question addresses whether the population analyzed in the
study sufﬁciently matches the population of interest to the
decision maker. Population characteristics to consider include
demographic characteristics such as age and sex, nationality, and
ethnicity; risk factors such as average blood pressure, cholesterol
levels, and body mass index; behaviors such as smoking; disease
history and onset, stage, and severity of the condition; past and
current treatments for the condition; and clinical issues such as
comorbidities. For rare diseases or special populations such as
pediatrics, the decision to conduct a prospective observational study
may be prompted by the general paucity of available information;
recruitment will necessarily be related to patient access.Are any relevant interventions missing?
This question addresses whether the interventions analyzed in
the study include ones of interest to the decision maker and
whether all relevant comparators have been considered. It is
frequently unrealistic that ALL interventions that could be con-
sidered to treat a disease or condition be included in the analysis;
however, omitting key interventions that represent standards of
care introduces the potential for bias and uncertainty. Interven-
tion characteristics should also be speciﬁed and deﬁned at a
detailed level. For technologies, this includes the device
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 4 3 – 1 5 6 149speciﬁcation and the technique used (e.g., screening for osteopo-
rosis: whether dual-energy X-ray absorptiometry or some other
scanning method was used and whether spine, hip, or wrist
measurements were taken). Questions to consider:
○ For drugs and biologics, were the doses, durations, and modes of
administration speciﬁed?
○ If usual clinical care was a comparator, were they adequately
described to determine whether they resemble the modes of care
in the decision setting?
○ For surgical interventions, was the skill level of providers,
posttreatment monitoring and care, and duration of follow-up
reported?Are the outcomes relevant?
This question asks what outcomes are assessed in the study and
whether the outcomes are meaningful to the patients the
decision maker is concerned with. Outcomes such as cardiovas-
cular events (e.g., rates of myocardial infarction or stroke),
mortality, patient functioning, health-related quality-of-life or
health status measures (e.g., scores from the short-from 36
health survey or the EuroQol ﬁve-dimensional questionnaire)
may be more relevant to a decision maker than surrogate or
intermediate end points (e.g., cholesterol levels).
Is the context (settings and practice patterns) applicable?
The context of the study refers to factors that may affect the
generalizability of the study ﬁndings to other settings. Factors
that should be considered may include the study time frame, the
payer or health system setting, provider characteristics, or the
geographic area. Some or all of these factors may be different
than the population to which the user wants to apply the study
results; however, if it is suspected that differences in these
factors may affect the treatment response, it should affect the
user’s judgment of the extent that these ﬁndings could be applied
to another setting.
Credibility
Credibility addresses the extent to which the study accurately
answers the question it is designed or intended to answer and is
determined by the design and conduct of the study. Central to
credibility assessment in the comparative effectiveness frame-
work is assessing the validity of the causal inferences of the
results. It focuses on issues of internal validity, measurement
error, and confounding. For example, the observed effect of a new
treatment may be due to the manner in which patients were
selected for treatment, or the degree to which patients
were followed and their outcomes reliably measured, and not
due to differences in treatment effectiveness. Appropriate study
design and analytic approaches can better separate the contri-
bution of the intervention to observed outcomes versus other
factors.
There are a wide range of resources available to assist users in
familiarizing themselves with some of the core concepts to
assess study quality including many textbooks in ﬁelds such as
econometrics, statistics, clinical research, epidemiology, and
health services research. Some contemporary resources that are
freely available that are focused on comparative effectiveness
research in the observational framework include Agency for
Healthcare Research and Quality’s “Developing a Protocol for
Observational Comparative Effectiveness Research: A User’s
Guide”; Patient-Centered Outcomes Research Institute’s Meth-
odological Standards; and the STrengthening the Reporting of
OBservational studies in Epidemiology initiative, which focuses
on study reporting [16,18,37].Design
Were the study hypotheses or goals prespeciﬁed a priori? As
stated in a previous report of an ISPOR Task Force, “One strength
of clinical trials is the requirement for a study protocol which
speciﬁes inclusion criteria for subjects, primary and secondary
outcomes, and analytic approach.” Although there are differing
views regarding a priori speciﬁcation of a research hypothesis
when conducting observational research, prior speciﬁcation min-
imizes the risk of outcome selection bias or “cherry-picking”
interesting ﬁndings and a related issue of observing spurious
ﬁndings because of multiple hypothesis testing [10]. For these
reasons, we recommend the practice of a priori speciﬁcation of
the research question, study design, and data-analysis plan in a
formal study protocol to assure end users that the results were
not the product of data exploration (i.e., “ﬁshing” or “dredging”
data: searching through the data until you ﬁnd something
interesting) [38]. This is not an indictment of exploratory data
analysis; rather that data exploration is more appropriate for
hypothesis generation, rather than hypothesis testing. Evidence
that prespeciﬁed hypotheses were formally stated in a protocol
includes registration on a publicly available Web site, such as
clinicaltrials.gov, or evidence of a review procedure or process
that may include disclosure of an institutional review board (IRB)
procedure, or using terms such as “prespeciﬁed,” “a priori,” or
“planned analyses” in the report. We note that most prospective
observational protocols will require an ethics or IRB review,
especially if they entail collection of speciﬁc assessments not
part of routine medical care. We also recognize that exploratory
analyses may be more likely in retrospective observational
studies that use existing records. Questions to consider:
○ Was the study registered on a publicly available Web site?
○ Was IRB review or approval obtained—suggesting that the
researchers used a formal protocol?
○ Was the study performed as a result of a research grant from a
well-established institution—suggesting that researchers had a
formal study proposal and analysis plan?If one or more comparison groups were used, were they
concurrent comparators or did they justify the use of historical
comparison group(s)? Concurrent comparators are derived from
the same population of subjects and are followed over the same
time frame; this approach avoids time-related confounding.
Alternatively, historical controls are derived from a population
of subjects derived from a time period prior to the treatment that
is compared. Concurrent comparators add more strength to
research ﬁndings, although the use of historical comparators
can be justiﬁed when a treatment becomes a standard of care and
nearly all subjects who could be treated either receive the new
treatment, or there are perceived ethical barriers to withhold the
new treatment. This suggests that a “no” answer to this question
does not automatically invalidate the credibility of study ﬁndings.
This issue is more commonly encountered in retrospective
observational studies and the choice of historical comparison
groups should be justiﬁed.
Was there evidence that a formal study protocol including an
analysis plan was speciﬁed before executing the study? Altering
study deﬁnitions, subject selection criteria, model speciﬁcations,
and other study procedures can have dramatic effects on study
ﬁndings and can introduce investigator biases [16–18]. Ideally,
study reports would be fully transparent about planned study
procedures. They should report ﬁndings based on the original
plan and be fully transparent regarding post hoc changes to the
analysis plan to justify those post hoc alterations. Unfortunately,
conventional reporting practices for observational studies are
Table 2 – Study designs used to minimize the effect
of confounding variables.
Inception cohorts are designated groups of persons assembled at a
common time early in the development of a speciﬁc clinical
disorder (e.g., at ﬁrst exposure to the putative cause or at initial
diagnosis), who are followed thereafter.
New-user design begins by identifying all the patients in a deﬁned
population (in terms of both people and time) who start a course
of treatment with the study medication. Study follow-up for end
points begins at precisely the same time as initiation of therapy
(t0). The study is further restricted to patients with a minimum
period of nonuse (washout) before t0.
Matching designs include a deliberate process to make two
comparable groups, a study group and a comparison group,
matched on factors extraneous to the main purpose for the
investigation but which might interfere with the interpretation
of the study’s ﬁndings.
Assessment of outcomes thought not to be affected by the
interventions compared may permit an assessment of residual
confounding [10]. These may be described as falsiﬁcation tests.
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what was preplanned and what was not [20]. The best evidence
that the study had an analytic plan would be to compare a study
report with its registry data; however, only a small fraction of
observational studies are registered. Trial registries provide the
best documentation that the study procedures followed a pre-
determined analytical plan. Few observational studies, however,
use trial registries, limiting the availability of outside conﬁrma-
tion of an analytical plan for observational studies. Alternatively,
users could rely on terms commonly used, such as prespeciﬁed or
“planned analyses” when describing the methods. The results
can also indicate prespeciﬁed analyses by declaring results that
were preplanned versus those that were post hoc. If the study
reports post hoc analyses, the user may cautiously infer
that other analyses were preplanned. In addition, when a study
reports peer-reviewed grant funding or an IRB review, it suggests
that an analysis plan was developed a priori. A prespeciﬁed
analysis plan cannot be assumed when a study does not
offer any indication that there was such a plan developed
beforehand.
Were sample size and statistical power to detect difference
addressed? An observational study attempts to create a compar-
ison across two samples just as its randomized counterpart and
therefore still requires a sample size or power calculation if
results are applied to a different study population [10]. Without
this, the reader is left with insufﬁcient information as to whether
the detectable difference should have occurred on the basis of the
expected size of the effect and in advance of the study.
In retrospective studies in which subjects are not prospec-
tively recruited, sample size estimates do not dictate the number
of subjects to be included in the study because the investigator
will typically include all available subjects recorded in the data
source and follow them for as long as subject data are recorded.
Including a sample size estimate or power calculation, however,
enables readers to interpret ﬁndings, particularly null ﬁndings.
Was a study design used to minimize or account for confound-
ing? A confounder is a factor that distorts the true relationship of
the study variables of central interest by virtue of being related to
the outcome of interest, but not related to the study question and
unequally distributed among the groups being compared. Some
study designs can provide stronger methods to deal with poten-
tial confounding that may occur because of lack of random-
ization. These include inception cohorts, new user designs, the
use of multiple comparator groups, matching designs, and
assessment of outcomes not thought to be affected by the
intervention compared (Table 2). Moreover, various considera-
tions factor into the choice of study design including feasibility,
cost, and ethical considerations.
The risk of residual, or unobserved, confounding is greater the
more dissimilar are the comparison groups. Design and analytic
approaches to ensure comparability of treatment and control
groups include matching designs, and analytic approaches such
as propensity scoring, and instrumental variable techniques.
These are described in more detail in previous ISPOR Task Force
reports [10–13]. Questions to consider:
○ Did the study design use strategies to minimize confounding such
as inception cohorts, new-user design, or matching?
○ Did the study analysis ensure comparability of comparison
groups through methods such as propensity scoring?Was the follow-up period of sufﬁcient duration to detect differ-
ences addressed? Depending on the condition studied and thedifference in effect of comparator interventions, the length of time
required to detect differences will vary. The more quickly and
more frequently outcome events are expected to occur, the shorter
the duration of follow-up is required (e.g., asthma exacerbations
can be detected with shorter observation periods in comparison
with hip fracture). The duration of follow-up is related to the
power of the study and its ability to detect differences. There may
be feasibility and cost limitations that affect the duration of
follow-up in prospective observational studies; however, this
should not affect the assessment of the credibility of its ﬁndings.
It is important to understand that in circumstances in which the
follow-up time used to assess outcomes overlaps with the time to
assess exposure (e.g., determine survival after someone is diag-
nosed or is discharged from a hospital and then use that same
follow-up period to determine whether he or she receives a
prescription) or when imposing a minimum follow-up time as
part of the study design, other biases can be introduced (e.g.,
immortal time bias) in the estimates of treatment effect [10–13,39]. Questions to consider:
○ Was the duration of follow-up appropriate to the population and
condition being studied?
○ Could the follow-up time have been inﬂuenced by the effects of
treatment (e.g., anticoagulation and stroke risk)?
○ Was the time frame to assess exposure before the beginning of
the follow-up time to record outcomes?Were the sources, criteria, and methods for selecting partici-
pants appropriate to address the study questions/hypotheses?
The sources, criteria, and methods for selecting participants for a
study should be similar for the different groups of patients being
assessed. Bias (e.g., a consistent measurable effect from system-
atic rather than random error and not from the intervention) can
be introduced if the comparator group or the data source or
methods for assessing or selecting patient groups vary [40]. Also,
the data source should provide some level of assurance that key
measures are reliably recorded. For retrospective studies, assur-
ance that relevant health information was captured will vary.
Administrative data sources should be checked to ensure that
subjects had continuous eligibility for health beneﬁts and were
eligible to receive all relevant sources of care. Not all persons
eligible for insurance in the United States will be eligible for
pharmacy or mental beneﬁts, for example. Studies that rely on
provider-supplied data such as electronic medical records (EMRs)
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provider network and not from other providers. Questions to consider:
○ Was there an adequate rationale provided for key inclusion and
exclusion criteria?
○ Was there an assurance that subject encounters or data were
adequately recorded over the entire study time frame for each
subject?Were the study groups selected so that comparison groups
would be sufﬁciently similar to each other (e.g., either by
restriction or recruitment based on the same indications for
treatment)? One of the most common starting points to enhance
the comparability of treatment groups is to restrict subjects to a
common set of conditions or patient characteristics. For example,
if one were to compare beta blockers and diuretics as antihyper-
tensive therapy, it would be important to restrict both treated
groups to those without any evidence of previous cardiovascular
disease including angina because beta blockers have a Food and
Drug Administration indication for angina (a strong risk factor for
subsequent myocardial infarction) whereas diuretics do not. A
study that does not include a strategy to ensure similarity
between groups could suffer from confounding by indication. Question to consider:
○ Did the study design ensure comparability of comparison groups
through methods such as restriction?Data
Were the data sources sufﬁcient to support the study? The data
sources should contain valid measures of treatment, outcome,
and covariates including confounding variables, possess a large
enough sample, and be of sufﬁcient duration to detect differ-
ences. Often a single data source will not contain all the
information necessary to conduct the study, and linkages to
other data sources may be necessary [22]. Prospective studies
may design study-speciﬁc data collection forms; they may also
rely on existing mechanisms to collect data. The quality of the
study data is a broad concept, and it can be affected by multiple
factors. Questions to consider:
○ Were all outcomes, exposures, predictors, potential confounders,
and effect modiﬁers clearly deﬁned?
○ Were the sources of data and details of methods of assessment
for each variable of interest adequately described?
○ Were the assessment methods and/or deﬁnitions the same across
treatment groups?
○ Were the reliability and validity of the data described, including
any data quality checks and data cleaning procedures?
○ Have the data sources been used previously for research?
○ Were reliable and valid data available on important confounders
or effect modiﬁers?Was exposure deﬁned and measured in a valid way? Exposure
to treatment is ideally documented by evidence that patients
actually took the medication or received the treatment, though
this is rarely done [23]. Exposure may be documented by evidence
of a prescription being written, being ﬁlled, a claim being ﬁled,
and measures of medication possession. Exposure is typically
deﬁned by whether a subject received (or did not receive) a
treatment; however, exposure may also be deﬁned in terms of
the intensity of exposure, including the dose and/or duration of
treatment(s). Questions to consider:
○ Does the study describe the data source(s) used in the study of
the ascertainment of exposure (e.g., pharmacy dispensing, gen-
eral practice prescribing, claims data, EMR data, chart review,
self-report, face-to-face interview)?
○ Does the study describe how exposure is deﬁned and measured
(e.g., operational details for deﬁning and categorizing exposure)?
○ Does the study discuss the validity of exposure measurement (e.
g., precision, accuracy, prospective ascertainment, and exposure
information recorded before outcome occurred)?Were the primary outcomes deﬁned and measured in a valid
way? Selection of primary outcomes is perhaps the most critical
part of study design [10,17]. Outcomes more directly observable,
such as laboratory measures, hospitalization, and death, may
require less sophisticated validation approaches than do out-
comes that are more difﬁcult to observe or rely on investigator
classiﬁcation and subjectivity, such as time to referral or medi-
cation adherence. Primary outcomes can be documented in a
patient chart (paper, EMR), inferred from claims (e.g., through
administrative codes suggesting hospitalization for myocardial
infarction), documented in a diary, or reported in a face-to-face
interview. The validity of outcome measures will vary on the
basis of the outcome measure, the context of the study, and the
data sources used and ultimately some degree of judgement will
be required.
In the retrospective framework, the validity of the outcome
measure may require more careful consideration, particularly
when the data source was not designed for the speciﬁc research
purpose, which is commonly encountered in studies that use
medical charts, EMRs, or administrative claims. Ideally, some
evidence of the validity (sensitivity, speciﬁcity, positive and
negative predictive values) of the outcome measure contrasted
with a measure where direct observation of the outcome could be
veriﬁed is reported. This can be accomplished by conducting a
substudy to verify the accuracy of the outcome deﬁnitions using
a more accurate or detailed data source (e.g., direct report by
subject or provider). Weaker evidence of the validity can be
inferred when previous studies that report the validity of the
outcome measures and deﬁnitions using a similar but different
data source (e.g., validity of outcome deﬁnition obtained from
one administrative data source that is structured similarly to the
study’s data source) are cited. Outcome measure deﬁnitions that
have been used in previous analyses permit comparison between
studies but do not ensure validity.
Was the follow-up time similar among comparison groups or
were the differences in follow-up accounted for in the analyses?
Patients may drop out of a study or discontinue medications for
many reasons including lack of effectiveness, adverse effects, or
routine life events such as moving or changing insurers. Differ-
ential follow-up between treatment groups can introduce a bias
in observed treatment effects. A credible study will explain as
best as possible the reasons for these differences and use
appropriate statistical techniques (reporting rates and utilizing
time to event analytic approaches that account for censoring) to
minimize the effect of variable follow-up time. Even when these
analytic approaches are used, immortal time bias cannot be ruled
out and is more likely when the duration of follow-up time is
affected by the treatment group selections or if being selected
into a treatment group is dependent on person time.
Analyses
Was there a thorough assessment of potential measured and
unmeasured confounders? The choice and effectiveness of
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environment and the experience of health care providers, as well
as the medical history of patients. Treatment inferences from
observational studies are all potentially biased from imbalances
across treatment groups on confounding variables whether the
variables are observed or not [10,17]. Confounding can be con-
trolled statistically using a wide arrange of multivariate
approaches. If a statistical model excludes a confounding varia-
ble, however, the estimates of treatment effects suffer from
omitted variable bias in just about all analyses except when a
technique such as instrumental variables or a regression dis-
continuation approach that uses a “natural” randomizer is under-
taken [26,41]. Ideally, one should look to see that the authors
have considered all potential confounding factors and conducted
a literature review to identify variables that are known to affect
the outcome variable. Unfortunately, this is not typically reported
in articles [13]. A table of potential confounders with citations to
previous research describing these associations is sometimes
available in an article and would be suggestive of an explicit
search to identify known confounding variables. In addition to a
literature search, credible research should use clinical judgment
or consensus techniques to identify confounders. Often, the data
will not contain information for some confounding variables (e.g.,
race, income level, and exercise level) and these variables will be
omitted from the analysis [26]. When the analysis does not
include key confounders, a thorough research report will discuss
the potential effect of these, including the direction and magni-
tude of the potential bias. Questions to consider:
○ Was there evidence that a literature search was performed to
identify all potential measured and unmeasured confounders?
○ Were known inﬂuential confounders unrecorded or not included
in the adjusted analyses?Were analyses of subgroups or interaction effects reported for
comparison groups? Exploring and identifying heterogeneous
treatment effects, or effect modiﬁcation, are some of the poten-
tial advantages of large observational studies. Interaction occurs
when the association of one exposure differs in the presence of
another exposure or factor. The most common and basic
approaches for identifying heterogeneous treatment effects are
to conduct subgroup analyses or to incorporate interaction terms
within the analysis [10,31]. Interactions may be explored using
additive or multiplicative approaches in which the differences in
effect depart from either the addition of effects of two factors or
exposures, or the multiplicative effect of those factors. Caution is
warranted when the main treatment effect is not signiﬁcantly
associated with the outcome, but signiﬁcant subgroup results are
reported (which could have been the result of a series of post hoc
subgroup analyses) [42].
Were sensitivity analyses performed to assess the effect of key
assumptions or deﬁnitions of exposure or outcome measures?
Various decisions must be made in designing a study. This
includes how populations, interventions, and outcomes are
deﬁned; how missing data are dealt with; how outliers are dealt
with; which analytic approaches were taken; and to what extent
unmeasured confounders may affect the results. A credible study
will indicate which of these decisions had an important effect on
the results of the analyses and will report the effect of using a
reasonable range of alternative choices on the results. Key issues
to consider include whether sensitivity analyses were reported
using different statistical approaches, and according to key
deﬁnitions; whether the analysis accounted for outliers and
examined their effect in a sensitivity analysis; and whether theauthors discussed or conducted a sensitivity analysis to estimate
the effect of unmeasured confounders on the observed difference
in effect. Questions to consider:
○ Were sensitivity analyses reported using different statistical
approaches?
○ Were sensitivity analyses reported to test the effect of key
deﬁnitions?
○ Did the analysis account for outliers and examine their effect in
sensitivity analysis?
○ Did the authors discuss or conduct a sensitivity analysis to
estimate the effect of unmeasured confounders on the observed
difference in effect?Reporting
When methods are described in sufﬁcient detail, it permits others
to replicate the analysis on similar data sets or to reproduce the
results if given access to the data set from the study. An adequate
description delineates all key assumptions, describes the key
study measure, and why a methodological approach was selected
over alternatives. Increasingly, published reports rely on online
appendices to more fully describe methods and results as these
should be checked in addition to any errata and letters to the
editor to identify corrections or alternative viewpoints in inter-
preting the data. Although there are several checklists that have
been developed to address adequacy of reporting including
minimum reporting standards for medical journals, a straightfor-
ward consideration is whether the reader can understand pre-
cisely how study authors arrived at their particular ﬁndings [16].
Was the number of individuals screened or selected at each
stage of deﬁning the ﬁnal sample reported? Reporting the
number of individuals screened at each stage of the selection
process is important to assess the potential selection bias of
participants and can provide cursory evidence that the study
procedures were implemented correctly. The ﬁnal analyzable
sample can most easily be interpreted when a text description
or a ﬂow diagram is provided that describes the initial pool of
potential subjects and the sample after each inclusion and
exclusion is applied. This allows the reader to more easily assess
the extent to which the analyzable sample may differ from the
target population and which criteria materially affected the ﬁnal
sample.
Were the descriptive statistics of the study participants
adequately reported? A basic summary of the observable char-
acteristics of the study population should be provided including
descriptive statistics on the mean value (and distribution where
appropriate) for demographic variables, prevalence of comorbid-
ities, and other potential confounders reported by treatment
groups to enable the reader to assess the comparability of treat-
ment groups and the potential for confounding. Vast differences
on key confounding measures may suggest a higher likelihood of
residual confounding even after adjusting for the observable
characteristics.
Did the authors describe and report the key components of their
statistical approaches? The authors should fully describe their
statistical approach and provide citations for any speciﬁc varia-
tion of econometric or statistical methods that they used. One
question to consider in assessing the adequacy of the statistical
reporting include whether the authors used statistical techniques
to examine the effect of multiple variables simultaneously (i.e.,
multivariate analysis) and whether they discussed how well the
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conduct a statistical test, such as r-squared, pseudo r-squared, c-
statistics, and c-indices, to demonstrate the predictive capacity of
the statistical model used. Other key items of statistical reporting
relate to statistical techniques used to adjust for multiple anal-
yses of the same data, reporting of unadjusted estimates of
treatment effects, and reporting of the full regression model in
either the publication or the appendix. Techniques commonly
used in observational studies include propensity score methods
and instrument variable methods. Some of these techniques may
require more extensive reporting of their development, use, and
evaluation. A guiding principle for statistical reporting is to
“Describe statistical methods with enough detail to enable a
knowledgeable reader with access to the original data to verify
the reported results” [43]. Questions to consider:
○ Did the authors describe and report the key components of their
statistical approaches?
○ Were any modeling assumptions addressed?
○ If the authors use multivariate statistical techniques, do they
discuss how well the models predict what they are intended to
predict?
○ Were unadjusted estimates of outcomes reported?
○ Was the full regression model (not just the adjusted treatment
effects) available in the publication or at least an appendix?
○ If propensity score methods were used, were the methods
appropriately described? Method of developing the propensity
score, use of the propensity score (matching, weighting, regres-
sion, etc.), evaluation of the propensity score (e.g., standardized
differences before and after matching).
○ If instrumental variable methods were used, were the methods
appropriately described (rational for the instrumental variable,
evaluation of the strength of the instrument).Were confounder-adjusted estimates of treatment effects
reported? Confounder-adjusted estimates of treatment effects
can be obtained in various ways. Most commonly, treatment
effects are estimated from a coefﬁcient of independent variable(s)
in a multivariate regression, or systems of equations that include
a set of control covariates that represent potential confounders.
Treatment effects may also be estimated by taking differences
from propensity-matched treated and comparison subjects. Any
nonrandomized study must report confounder-adjusted esti-
mates if it is attempting to make any inference regarding the
effects from treatment. Unadjusted estimates should also be
reported to allow for comparison with the adjusted results.
Did the authors describe the statistical uncertainty of their
ﬁndings? There will always be uncertainty when evaluating
outcomes in observational research because estimates must be
based on population samples. Uncertainty from sampling should
be presented in the form of either a Bayesian credibility interval
(range of values that is likely to contain the true size of the effect
given the data) or a CI (range of values that is likely to contain the
true estimate, e.g., 95%). P values can provide some sense of
uncertainty but are not sufﬁcient for reanalysis. Because they are
a product of both uncertainty and the magnitude of the effect
observed, they can be misleading when either sample popula-
tions or effect sizes are large.
Was the extent of missing data reported? There is considerable
opportunity to introduce bias into estimates of treatment effects
if data are missing [28,44]. Missing data can occur in prospective
observational studies because many studies rely on secondarydata sources that rely on routine data entry. Because it is possible
that the reason for the missing data is related to the reason for
observed treatment effects, the extent of missing data should be
reported. The potential for bias from missing data can be further
explored in sensitivity analyses or through analyses that attempt
to correct for missing data by making assumptions. Credibility i
s enhanced if the authors indicate that an a priori analytic
strategy to deal with missing data (including any data imputa-
tion method) was explicitly created as part of their data analysis
plan.
Were absolute and relative measures of treatment effect
reported? Reporting the effect of treatment(s) in both absolute
and relative terms provides the decision maker the greatest under-
standing of the magnitude of the effect [45]. Absolute measures of
effect included differences in proportions, means, rates, number
needed to harm, and number needed to treat and should be
reported for a meaningful time period. Relative measures of effect
are rate ratios, proportions, or other measures and include odds
ratios, incidence rate ratios, relative risks, and hazard ratios.
Interpretation
Were the results consistent with previous known information or
if not was an adequate explanation provided? To aid interpre-
tation of research, study authors should undertake a thorough
review of the literature to compare their ﬁndings to all known
previous ﬁndings exploring the same or similar objectives.
Research authors should provide plausible explanations for dis-
parate ﬁndings and identify methodological differences or
advance a theoretical or biologic rationale for the differences.
Authors should provide plausible explanations that have led to
ﬁndings that are different in direction or magnitude.
Are the observed treatment effects considered clinically mean-
ingful? In analyses of large observational studies, sometimes
relatively minor differences between treatment groups can attain
levels of statistical signiﬁcance because of the large sample sizes.
The results should be interpreted not only in terms of their
statistical association but also by the magnitude of effect in terms
of clinical importance. Some authors may identify previously
developed minimally important clinical differences to support
their assertions. In addition, the larger the treatment effect that is
observed, the smaller the chances that residual confounding can
change a signiﬁcant ﬁnding to a null ﬁnding.
Are the conclusions supported by the data and analysis
presented? Overstating the implications of the study results is
commonly encountered in the literature [46]. The study should be
fully transparent describing the study limitations and importantly
how study limitations could affect the direction and magnitude of
the ﬁndings and ultimately the study conclusions. Users of a study
should consider whether conclusions are cautious and appropriate
given the objectives, limitations, multiplicity of analyses, results
from similar studies, and other relevant evidence. Authors should
discuss the limitations of the study, including the potential direc-
tion and magnitude of any potential bias, to help users of the study
understand the degree to which these limitations may reduce the
strength of the casual inferences.
Was the effect of unmeasured confounding discussed? Unmeas-
ured confounding is always a potential issue in any observational
research framework. Unmeasured confounding is more likely to
bias the results when patients might be channeled to one treat-
ment over another with studies that investigate known or likely
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are less likely to be considered in the clinician’s or patient’s decision
process, and, in turn, are less likely to suffer from confounding. A
good discussion will identify factors thought to be confounders that
were not recorded or were unmeasurable, and identiﬁes the poten-
tial direction of the bias. A credible study would ideally assess
residual confounding through simulations to explore how strongly a
confounder would have to be correlated with treatment and out-
come to move the results to a null ﬁnding.
Conﬂicts of interest
Two questions were used in the conﬂicts of interest domain in all
the questionnaires.
Were there any potential conﬂicts of interest? Conﬂicts of
interest may be stated by authors; however, reviewers may also
seek information from public sources including Web-based curric-
ula vitae or faculty pages. In some cases, conﬂicts are not stated in a
research report simply because of editorial policy rather than a lack
of their existence. Although some journals adhere strictly to uni-
form standards for disclosing conﬂicts, such as those promoted by
the International Committee of Medical Journal Editors, others may
not. Readers should not misinterpret absence of a stated conﬂict as
evidence of absence of a conﬂict.
If there were potential conﬂicts of interest, were steps taken to
address these? Potential conﬂicts of interest may include ﬁnan-
cial interests in the study results, desire for professional recog-
nition, or other nonmonetary incentives. Steps to address
potential conﬂicts of interest include disclosure of any potential
conﬂicts of interest; involving third parties in the design, con-
duct, and analysis of studies; and agreements that provide
independence of researchers (including freedom to publicly dis-
seminate results) from funding entities [30].Summary of Questionnaire Results
The Web-based version of the questionnaire provides a summary
of the assessments as follows:
In evaluating this study, I made the following judgments: I found the study (relevant, not relevant) for decision making because
I considered that the population/interventions/outcomes/setting
(applied, did not apply) to the decision I am informing. I found the study (credible, not credible) for decision making because:
○ There (were, were not any) fatal ﬂaws—that is, critical elements
that call into question the validity of the ﬁndings.
▪ The presence of a fatal ﬂaw suggests signiﬁcant opportunities
for the ﬁndings to be misleading and misinterpreted; extreme
caution should be used in applying the ﬁndings to inform
decisions.
▪ The following domains contained fatal ﬂaws:
○ There are strengths and weakness in the study:
▪ The following domains were evaluated as strengths:
▪ The following domains were evaluated as weaknesses:Discussion
User Testing
Following preliminary testing by members of the four task forces,
the wording of some of the questions was modiﬁed. The revised
questionnaire was made available to volunteers from the payer
community (members of the AMCP) as well as thepharmaceutical industry. Ninety-three volunteers were solicited
to participate. Each volunteer was asked to test one question-
naire using three studies and rate them accordingly. Studies
were provided that were previously rated by the Task Force as
either “good quality,” “medium quality,” or “poor quality.” Sixty-
ﬁve volunteers participated, of which 25 were assigned to the
prospective observational study questionnaire; the response rate
from this group was 72%. Twenty were assigned to the retro-
spective observational study questionnaire; the response rate
from this group was 70%. Although there were not enough users
to perform a formal psychometric evaluation, the good-quality
studies were generally rated as sufﬁcient with respect to credi-
bility, while the poor-quality studies were generally rated not
sufﬁcient. Based on the answer to the question: “Is the study
‘Sufﬁciently’ or ‘Insufﬁciently’ credible to include in the body of
evidence?” there was 59% and 54% multirater agreement among
ratings provided for the prospective and retrospective question-
naires, respectively. Ratings were not provided 15% to 36% of
the time. Multirater agreement exceeded 80% for 16 of the 28
original items in the retrospective credibility domains. In the
original format, there were supplementary questions and few
test users completed those and hence these were not included
as speciﬁc items in this revised questionnaire. These results
were used to modify the questionnaire to its current format and
enhanced explanations were developed to increase interrater
agreement.Educational Needs
Internationally, the resources and expertise available to inform
health care decision makers vary widely. Although there is
broad experience in evaluating evidence from RCTs, there is
less experience and greater skepticism regarding the value of
other types of evidence [12,18]. The volume and variety of real-
world evidence, however, is increasing rapidly with the ongo-
ing adoption of electronic EMRs along with the linkage of
claims data with laboratory, imaging, and EMR data. Volume,
variety, and velocity (the speed at which data are generated) are
three of the hallmarks of the era of “big data” in health care. The
amount of information from these sources could easily eclipse
that from RCTs in coming years. This implies that it is an ideal
time for health care decision makers and those who support
evidence evaluation to enhance their ability to evaluate this
information.
Although there is skepticism about the value of evidence from
observational, network meta-analysis/indirect treatment com-
parison, and modeling studies, they continue to ﬁll important
gaps in knowledge for payers, providers, and patients. ISPOR has
provided Good Research Practice recommendations on what
rigorous design, conduct, and analysis looks like for these sources
of evidence [10–13,47,48]. These questionnaires, including the
one discussed in this report, are an extension of those recom-
mendations and serve as a platform to assist the decision
maker in understanding what a comprehensive evaluation of
this research requires. By using this questionnaire, our intent
is to make observational evidence more accessible and raise
the level of sophistication by decision makers and the bodies
that support them through the use and interpretation of
evidence.
To that end, we anticipate additional educational efforts and
promotion of these questionnaires and that they will be devel-
oped and made available to an increasing number of health care
decision makers. In addition, an interactive Web-based tool
has been developed at https://healthstudyassessment.org/ to
facilitate uptake and support the educational goal of the
questionnaire.
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